Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
  1. Home
  2. Publications
  3. Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Authors:
  • MSMansi Saxena
    Mansi Saxena
  • TMThomas U. Marron
    Thomas U. Marron
  • JKJulia Kodysh
    Julia Kodysh
  • JFJohn P. Finnigan
    John P. Finnigan
  • SOSayali Onkar
    Sayali Onkar
  • AKAnna Kaminska
    Anna Kaminska
  • KTKevin Tuballes
    Kevin Tuballes
  • RGRuiwei Guo
    Ruiwei Guo
  • RSRachel Lubong Sabado
    Rachel Lubong Sabado
  • MMMarcia Meseck
    Marcia Meseck
  • TOTimothy J. O’DOnnell
    Timothy J. O’DOnnell
  • RSRobert P. Sebra
    Robert P. Sebra

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2159-8290.32697901
Abstract
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)
Keywords
  • CLINICAL TRIAL RESULTS
  • IMMUNOLOGY
  • CYTOKINES
  • T CELL EXHAUSTION
  • TUMOR ANTIGENS/NEOANTIGENS
  • IMMUNOTHERAPY
  • CANCER VACCINES
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.